We are live on ! Find out more
MYGN icon

Myriad Genetics
MYGN

Fund managers haven’t disclosed any holdings of MYGN yet.

MYGN Hedge Fund Activity: Q1 2026 in Review

202 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2026, worth a combined $518M — down 8.7% from $568M a quarter earlier.

Sellers outnumbered buyers: 48 funds closed out of MYGN and 32 opened new positions — a net loss of 16 holders — while 68 trimmed existing stakes and 75 added.

The largest buyer was Acadian Asset Management, adding an estimated $6.89M. The largest seller was BlackRock, cutting an estimated $33.4M.

  • 202 institutional investors held Myriad Genetics (MYGN) as of Q1 2026, down from 221 in Q4 2025.
  • Funds reported $518M of Myriad Genetics stock for Q1 2026, down 8.7% quarter-over-quarter.
  • 32 funds opened new Myriad Genetics positions in Q1 2026 and 48 closed out, a net change of -16 holders.
  • The largest Myriad Genetics buyer in Q1 2026 was Acadian Asset Management, an estimated $6.89M added.
  • The largest Myriad Genetics seller in Q1 2026 was BlackRock, an estimated $33.4M sold.

Based on aggregated 13F filings for Q1 2026.